Zacks Research Has Pessimistic Outlook of BIO Q4 Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Stock analysts at Zacks Research decreased their Q4 2025 EPS estimates for Bio-Rad Laboratories in a report released on Wednesday, December 18th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $3.21 for the quarter, down from their previous forecast of $3.28. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.29 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q2 2026 earnings at $3.16 EPS.

A number of other brokerages also recently issued reports on BIO. Wells Fargo & Company initiated coverage on Bio-Rad Laboratories in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 price objective on the stock. StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Citigroup raised their price objective on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, Royal Bank of Canada upped their price objective on Bio-Rad Laboratories from $369.00 to $481.00 and gave the stock an “outperform” rating in a report on Monday, December 9th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $394.20.

Bio-Rad Laboratories Price Performance

BIO stock opened at $330.53 on Monday. The firm has a 50 day moving average of $340.22 and a 200-day moving average of $323.44. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $9.25 billion, a P/E ratio of -12.09 and a beta of 0.90. Bio-Rad Laboratories has a 12 month low of $262.12 and a 12 month high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.16 by $0.85. The firm had revenue of $649.70 million for the quarter, compared to the consensus estimate of $628.18 million. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The business’s quarterly revenue was up 2.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.33 earnings per share.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. First Eagle Investment Management LLC increased its position in Bio-Rad Laboratories by 32,296.9% during the 2nd quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company’s stock valued at $173,773,000 after purchasing an additional 634,311 shares during the period. Principal Financial Group Inc. raised its stake in Bio-Rad Laboratories by 95.6% in the third quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company’s stock worth $14,836,000 after buying an additional 21,669 shares in the last quarter. Mawer Investment Management Ltd. lifted its holdings in Bio-Rad Laboratories by 63.0% in the third quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock worth $72,900,000 after buying an additional 84,237 shares during the period. Verition Fund Management LLC grew its holdings in shares of Bio-Rad Laboratories by 193.3% during the 3rd quarter. Verition Fund Management LLC now owns 3,470 shares of the medical research company’s stock worth $1,161,000 after acquiring an additional 2,287 shares during the period. Finally, Louisiana State Employees Retirement System raised its position in shares of Bio-Rad Laboratories by 341.7% in the 3rd quarter. Louisiana State Employees Retirement System now owns 5,300 shares of the medical research company’s stock worth $1,773,000 after acquiring an additional 4,100 shares in the last quarter. Institutional investors own 65.24% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.